

٠.

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Docket No.: PF126P1D1

w/attach

Application No.: 09/348,815

In re Patent Application of: Li et al.

Group Art Unit: 1635

• • •

Filed: July 8, 1999

Examiner: J. Zara

For: Connective Tissue Growth Factor-2

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, DC 20231

Dear Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorney for Applicants hereby directs the Examiner's attention to references AA-AF listed on the attached Form PTO/SB/08. Copies of the references are enclosed.

Applicants wish to bring to the attention of the Examiner that SEQ ID NO:1 and corresponding cDNA clone of this application are related to SEQ ID NO:23836 in copending U.S. Patent Application Serial No. 09/912,292. A legible copy of that portion of U.S. Patent Application Serial No. 09/912,292 which caused it to be listed on the attached Form PTO/SB/08 is submitted herewith as reference AA.

The listed references are presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 C.F.R. § 1.104(a) concerning the Examiner's duty to consider and use any such information. Applicants respectfully request that the Examiner make the listed references of record in the file history of the application, and consider the information contained therein during the prosecution of this application.

Identification of the listed references is not to be construed an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants

RECEIVED
JUN 0 3 2002
TECH CENTER 1600/2900

do not waive any rights to take appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

Pursuant to 37 C.F.R. § 1.97(b)(1), since this Supplemental Information Disclosure Statement is being submitted within three months of (i.e., concurrently with) the filing of a Continued Prosecution Application Request, no fee is believed due in connection herewith. However, should the Commissioner determine otherwise, please charge such fee or credit any overpayment to our Deposit Account No. 08-3425.

Respectfully submitted,

Dated: May 29, 2002

Registration No.: 46,903

HUMAN GENOME SCIENCES, INC.

9410 Key West Avenue Rockville, Maryland 20850

(301) 315-2723

MMW/JMM/LT/ba